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Abstract
Background: We previously reported that adoption of an “open” envelope glycoprotein (Env) to expose the CD4
binding site for efficient receptor binding and infection of cell targets such as macrophages that express low levels
of the receptor represents an early event in the process of coreceptor switch in two rapidly progressing (RP) R5
SHIVSF162P3N-infected rhesus macaques, releasing or reducing Env structural constraints that have been suggested to
limit the pathways available for a change in coreceptor preference. Here we extended these studies to two
additional RP monkeys with coreceptor switch and three without to confirm and identify additional factors that
facilitated the process of phenotypic conversion.
Results: We found that regardless of coreceptor switching, R5 viruses in SHIVSF162P3N-infected RP macaques evolved
over time to infect macrophages more efficiently; this was accompanied by increased sCD4 sensitivity, with
structural changes in the CD4 binding site, the V3 loop and/or the fusion domain of their Envs that are suggestive
of better CD4 contact, CCR5 usage and/or virus fusion. However, sCD4-sensitive variants with improved CD4
binding were observed only in RPs with coreceptor switch. Furthermore, cumulative viral load was higher in RPs
with than in those without phenotypic switch, with the latter maintaining a longer period of seroconversion.
Conclusions: Our data suggest that the increased virus replication in the RPs with R5-to-X4 conversion increased
the rate of virus evolution and reduction in the availability of target cells with optimal CD4 expression heightened
the competition for binding to the receptor. In the absence of immunological restrictions, variants that adopt an
“open” Env to expose the CD4 binding site for better CD4 use are selected, allowing structural changes that confer
CXCR4-use to be manifested. Viral load, change in target cell population during the course of infection and host
immune response therefore are interdependent variables that influence R5 virus evolution and coreceptor switch in
SHIVSF162P3N-infected rhesus macaques. Because an "open" Env conformation also renders the virus more
susceptible to antibody neutralization, our findings help to explain the infrequent and late appearance of X4 virus
in HIV-1 infection when the immune system deteriorates.
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Entry of the human immunodeficiency virus (HIV) is
initiated by binding of the gp120 surface subunit of the
viral envelope protein (Env) to the cellular receptor CD4
and either the CCR5 (R5 viruses) or CXCR4 (X4 viruses)
coreceptor on the target cell [1]. Most HIV-1 transmis-
sions result in a predominantly R5 virus infection [2-4].
With time, X4 variants arise and coexist with R5 variants
in ~50% of subtype B infected individuals, and their
emergence is associated with rapid CD4+ T cell loss and
disease progression [5,6]. The determinants of pheno-
typic change from R5 to X4 map largely to the V3 region
of the exterior envelope glycoprotein, gp120 [7], and can
be inferred by analysis of the amino acid sequence of
this region [8]. The underlying factors for virus corecep-
tor switch late in infection however remain uncertain,
but several hypotheses that include high viral load and
evolutionary rate, changes in target cell populations dur-
ing the course of infection and/or differential immune
recognition of X4 and R5 viruses have been proposed
[9,10]. Because the presence of X4 virus is associated
with poorer clinical prognosis and is a major limitation
to the clinical use of CCR5 inhibitors [11-15], a better
understanding of the pathway and selective pressures for
the emergence of X4 virus should provide important
insights into HIV-1 pathogenesis and treatment.
We recently reported coreceptor switch in macaques
infected intravenously (iv), intrarectally (ir) or intravagin-
ally (ivag) with the late R5 SHIVSF162P3N isolate [16-18].
The majority of infected macaques in which X4 virus
emerged are rapid progressors (RP), with a clinical course
that is characterized by persistent high levels of virus rep-
lication, early onset of clinical disease and undetectable or
transient antiviral antibody titers that usually wane within
3-4 weeks of virus inoculation. Nevertheless, we showed
that the genetic requirements for coreceptor switch in
SHIVSF162P3N-infected RPs overlapped with those reported
in humans that developed neutralizing antibodies
[8,16,17,19,20], and transitioned similarly through dual-
tropic intermediates with reduced replicative capacity and
less efficient coreceptor use [21-24]. Furthermore, consist-
ent with findings in HIV-1 infected patients [25-27], the
appearance of X4 virus follows rather than precedes the
initial decline of CD4+ T cells in the infected maca-
ques. Since the newly emerging CXCR4-using viruses
in both hosts are highly sensitive to neutralization with
antibodies directed against the CD4 binding site
[16,17,28,29], these observations suggest that immuno-
logical impairment provides a selective advantage for
emergence and expansion of X4 virus. Thus, the mech-
anistic pathways and selection factors underlying
phenotypic conversion are likely similar in some HIV-1
infected patients and in SHIVSF162P3N-infected RP
monkeys.
For these reasons, we conducted a study to explore
the mechanistic basis and blockade(s) for virus corecep-
tor switch in two R5 SHIVSF162P3N-infected RPs [30].
We found that R5 viruses evolved over time in these two
macaques to become increasingly sensitive to sCD4, in-
dicative of an “open” envelope conformation that
exposes the CD4 binding site and improves receptor
binding. Indeed, we observed that the increase in sCD4
sensitivity of the evolving R5 viruses correlates with the
ability of their Envs to bind CD4 more efficiently as well
as to mediate infection of cell targets that express low
levels of the receptor. Furthermore, major antigenic
changes in Env gp160 of the R5 viruses, including
changes in the V3 loop that are important for coreceptor
engagement, were seen near and at the time of corecep-
tor switch, consistent with global changes in Env con-
formation and structural plasticity that facilitate the
remodeling needed to expand or switch to CXCR4
usage. These findings led us to propose that adoption of
an "open" Env to expose the CD4 binding site for effi-
cient CD4 binding and infection of CD4
low cells repre-
sents an early event in the process of coreceptor switch,
releasing or reducing Env structural constraints that
have been suggested to limit the mutational pathways
available for a change in coreceptor preference. Because
these studies were limited with respect to the number of
animals, and not all R5 SHIVSF162P3N-infected RP maca-
ques exhibited coreceptor switch, the present work is
conducted in two additional RPs with and three without
tropism switch to verify and extend our earlier observa-
tions, and to identify additional factors that facilitated
the process of R5-to-X4 conversion.
Results
R5 viruses evolve in RPs with coreceptor switch to infect
primary macrophages more efficiently by improving their
CD4 binding
To lend further support to our proposed mechanistic
model that exposure of the CD4 binding site for
improved CD4 binding and infection of CD4
low cells is
an early step in coreceptor switching, we generated
viruses pseudotyped with CCR5-using Envs amplified
over time from two additional SHIVSF162P3N-infected
RPs with coreceptor switch (DE86, DG08). In addition
to clinical indicators such as CD4 T cell loss in the per-
iphery and lymph nodes, coreceptor switch in our stud-
ies is defined genotypically and phenotypically by
envelope gp120 V3 sequence analysis in combination
with an assessment of the ability of viruses recovered
from blood and nodes of the infected animals at end-
stage disease to utilize CXCR4. We determined the sen-
sitivity of the evolving viruses to sCD4 and the CCR5
inhibitor PSC-RANTES as indirect measurements of
their CD4 and CCR5 utilization efficiencies, respectively
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macrophages that express low levels of the CD4 receptor
and their gp120s to bind CD4-Ig was also examined.
High and sustained levels of virus replication were seen
in both rhesus monkeys, with progression to disease
within 30 weeks post-infection (wpi) (Figure 1A). Two
independent systemic R5-to-X4 switch events were iden-
tified in DG08 seven weeks prior to euthanasia at 20 wpi
[17], with one in DE86 that is localized to the lymph
node at the time of necropsy (12 wpi) (unpublished data;
[33]). Blood CD4+ T cell count fluctuated in DE86, but
declined in DG08, with precipitous loss towards end-
stage disease. DG08 failed to mount a detectable anti-
SHIV antibody response while the response in DE86 was
transient, waning at 4 wpi (Table 1). Full-length gp160
Envs were derived by bulk PCR amplification from
plasma collected at 2, 4, 5, 8 and 12 wpi for DE86, and
at 2, 4, 8, 11, 12 13, 14, 16 and 20 wpi for DG08. Three
or more CCR5-using Env clones per time point were
analyzed.
We found no significant difference in the entry effi-
ciency (Figure 2A) or susceptibility to PSC-RANTES in-
hibition of R5 viruses evolving over time in DE86
(Figure 2B). In contrast, R5 viruses that evolved follow-
ing the time of emergence of dual- and X4-tropic viruses
in DG08 infected the CD4
hiCCR5
hi TZM-bl cells less ef-
ficiently (8.4- and 13-fold reduction in RLU for the w16
and w20 viruses as compared to the early w2-4 viruses
respectively), with a 1.5- to 2-fold increase in susceptibil-
ity to PSC-RANTES inhibition of the w16 and w20
viruses that is suggestive of less efficient CCR5 usage.
These findings of decreased replication and efficacy of
CCR5 use with disease progression in DG08 are consist-
ent with results in HIV-1 infected individuals with de-
tectable CXCR4-using variants [6,34,35] and in the two
SHIVSF162P3N-infected RP macaques with coreceptor
switch studied earlier (BR24, CA28) [30]. Moreover, in
agreement with our previous data, R5 viruses in both
DE86 and DG08 evolved to become increasingly sensi-
tive to inhibition with CD4-IgG2, a tetrameric soluble
CD4 (sCD4) construct based on IgG. For both monkeys,
the increase in sCD4 sensitivity that preceded the
coreceptor switch occurred in the presence of adequate
CD4+ T cell numbers (300-500 CD4+ T cells per ul
blood; Figure 2C). Compared to the early w2 replicating
virus, which required 1.45 μg/ml sCD4 to achieve 50%
neutralization (IC50), a significant 3-4.5 fold increase in
susceptibility was evident for viruses prior to (w8) and at
the time of (w12) coreceptor switch in DE86. The w2
replicating virus in DG08 was as sensitive to sCD4
neutralization as the late DE86 viruses (IC50 0.42 μg/ml),
but viruses replicating two weeks later were slightly
more sCD4 resistant (IC50 0.6 μg/ml). Compared to the
w4 viruses, R5 viruses present before (w11, w12) and
after (w14, w16, w20) the time of switch in DG08 were
also significantly more sCD4 sensitive, with a rebound in
sCD4 resistance close to the baseline level seen at the
time of switch (w13).
Importantly, and in support of our earlier findings
[30], the increase in sCD4 sensitivity of the evolving R5
viruses in DE86 and DG08 was accompanied by a corre-
sponding increase in the binding of the gp120s to CD4-
Figure 1 Viral load and CD4+ T cell count in SHIVSF162P3N–infected macaques with (A) and without (B) coreceptor switch. (A) Macaque
DE86 was infected by the intravenous route and DG08 was inoculated intrarectally. Dashed line designates the time of dual-tropic and X4 virus
emergence in these animals. (B) Macaques BT78, CC39 were infected intravenously while DN57 was challenged intrarectally. Time to euthanasia
for the five RPs is: w12 (DE86), w20 (DG08), w13 (BT78), w12 (CC39) and w30 (DN57).
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low amounts of the CD4 receptor (Figure 3A). The
exceptions were R5 viruses present one week prior (w12)
and at the time of coreceptor switch (w13) in DG08.
Despite sCD4 sensitivity that was comparable to the w11
viruses, the w12 viruses in DG08 exhibited diminished
ability to infect primary macrophages, with lower gp120/
CD4-Ig binding as well. We did not observe any amino
acid changes in the CD4 binding site, the Phe43 cavity
or the inner domain layers of gp120 that could explain
the loss in macrophage infection and CD4 binding of
the w12 Envs. This dissociation between sCD4 sensitiv-
ity, better CD4 binding and infection of CD4
low cells in
DG08 prior to the time of switch had previously been
observed in BR24 [30], suggesting that mechanism(s)
other than exposure of the CD4 binding site (BS) for
better CD4 use is conferring sCD4 sensitivity to the w12
viruses. Decreased infection of primary macrophages
and receptor binding was also seen for the w13 viruses,
but as noted above, there was a 2-fold increase in sCD4
resistance for R5 viruses at this time point.
Changes in envelope glycoprotein antigenic structure
near and at the time of tropism switch
Marked changes in structure or accessibility of the
CD4BS and V3 loop of gp120 and the pre-hairpin inter-
mediate of gp41 were observed near the time of switch in
our prior study of two RPs [30]. Accordingly, we probed
the structure of the evolving R5 viruses in DE86 and
DG08 by assessing their susceptibility to neutralization
with the anti-CD4BS mAb b12, the anti-V3 loop mAb
447-52D and T20, which binds a triple-stranded coiled
coil activated fusion intermediate composed of the N-
terminal heptad repeat (HR-1) region of gp41. Results
showed that the changes in sCD4 sensitivity and receptor
use of the R5 viruses evolving around the time of core-
ceptor switch in the two macaques coincided with modu-
lations in Env conformations. For DE86, there was a
significant increase in b12 and 447-52D susceptibility for
viruses close to (w8) and at the time of (w12) coreceptor
switch that may be indicative of changes in the structure
and/or accessibility of the CD4 and coreceptor binding
sites (Figure 3B). A significant increase in T20 sensitivity
of the w12 viruses is suggestive of greater exposure or a
longer half-life of the gp41 HR-1 groove on the Envs of
these viruses. The changes in the antigenic structure of
R5 Envs around the time of coreceptor switch in DG08,
the macaque that harbored two independent R5-to-X4
evolutionary pathways, were more complex. Compared
to the acute viruses, a statistically significant increase in
b12 sensitivity was evident at 8 wpi, and remained so ex-
cept for the w11 and w12 viruses. T20 sensitivity was also
significantly increased, with the exception of viruses prior
to (w12) and at the time of switch (w13). Furthermore, a
dramatic decrease in 447-52D sensitivity was seen for the
w11 viruses. Taken together, the data support Env struc-
tural changes near and following the time of switch in
DE86 and DG08. These changes involve the V3 domain
that is important for coreceptor binding and the fusion
peptide in gp41 that can modulate coreceptor specificity
[36]. The frequent blood samplings in DG08 (weekly be-
fore, during and after tropism switch) provided a more
dynamic picture of R5 virus evolution in RPs with mul-
tiple and concurrent coreceptor-switching events.
R5 viruses in RPs without coreceptor switch also evolved
to infect macrophages more efficiently, but this was not
accompanied by an increase in CD4 binding
To determine if acquisition of better CD4 binding is a
unique characteristic of the R5 viruses in RPs with core-
ceptor switch, we characterized CCR5-using Envs over
Table 1 Anti-SHIV binding antibody in R5 SHIVSF162P3N-
infected RP macaques
Week
post-
infection
With coreceptor switch Without coreceptor switch
BR24 CA28 DE86 DG08 BT78 CC39 DN57
0- - - - - - -
1- + - - - + -
2+ + + - + - -
3+ + + - + - +
4+ - + - + - +
5- - - +
6- - +
7+ - - + -
8- - + +
9- - +
10 - + +
11 - - +
12 - -* - -*
13 - -* +
14 -
15 -* +
16 -
17 +
18 -
19 +
20 - -*
24 -
25 +
28 -*
30 +*
*Indicates time of euthansia. BR24, CA28, DE86, BT78 and CC39 were infected
intravenously, while DG08 and DN57 were infected intrarectally. BR24 and
CA28 are RPs from an earlier study [30].
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with no overt signs of coreceptor switch. BT78, CC39
and DN57 progressed to disease at 13, 12 and 30 wpi re-
spectively, with preservation of peripheral and lymphoid
CD4+ T cells at the time of euthanasia [17,33]
(Figure 1B). Weak SHIV-specific binding antibody re-
sponse could be detected throughout the course of in-
fection in DN57, but was less persistent in BT78 (waned
after 10 wpi) and absent in CC39 (Table 1). We derived
full-length Envs by bulk PCR amplification of plasma
collected at 1, 2, 5, 8 and 13 wpi for BT78, at 1, 4, 6, 9
and 12 wpi for CC39, and at 2, 4, 6, 10, 17, 25 and 30
wpi for DN57. At least three Env clones from each time
point were assessed for their ability to mediate entry and
PSC-RANTES susceptibility. Results showed that Envs
amplified over time from BT78 and CC39 mediated
comparable entry into TZM-bl cells, but the late viruses
in DN57 (w17, 25 and 30) showed a 2- to 7-fold
reduction in entry efficiency compared to the acute w2
viruses (Figures 4A). PSC-RANTES sensitivity fluctuated
for the evolving R5 viruses in CC39 and DN57, but a
trend towards resistance was seen in BT78 (Figure 4B).
The difference in PSC-RANTES susceptibility between
the early w2 and end-stage w13 viruses in BT78
approaches significance (p=0.06), consistent with reports
that the late R5 viruses in HIV-1 infected individuals
without detectable X4 viruses use the CCR5 coreceptor
better [6,37-41].
sCD4 sensitivity, gp120/CD4-IgG binding and infec-
tion of primary macrophages of the evolving R5 viruses
in the three RPs without evidence of coreceptor switch
were then determined (Figure 5). Increase in sCD4 sen-
sitivity was seen for R5 viruses evolving over time in
BT78 and DN57, but was transient in CC39. The in-
crease was ~3-fold for the end-stage (w13) viruses rela-
tive to the early (w2) viruses in BT78, but was significant
Figure 2 Entry efficiency, PSC-RANTES and sCD4 sensitivity of R5 viruses evolving over time in DE86 and DG08. Entry of luciferase
reporter viruses expressing CCR5-using envelopes into TZM-bl cells expressed as relative light unit (RLU) (A), and susceptibility of the reporter
viruses to neutralization with PSC-RANTES (B) and sCD4 (C) were determined. The dashed vertical line indicates time of tropism switch in DE86
(12 wpi), and DG08 (13 wpi). The numbers in the brackets indicate the number of clones analyzed at each time point. Absolute CD4+ T cell
count in the animal over the course of infection is shown in (C) for reference and values above the bars indicate fold increase in sCD4 sensitivity
relative to that of the w2 viruses. * P<0.05 (Mann-Whitney U test). Data are representative of 2-3 independent experiments (error bars, s.d.).
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viruses. Values above the bars indicate fold increase in sCD4 sensitivity of evolving viruses compared to early viruses, and the vertical dashed line
indicates the time of coreceptor switching. sgp120 binding to CD4-Ig was normalized to that of sgp120 binding to polyclonal serum from HIV-1
infected individuals. Infectivity in mΦ that express low levels of CD4 was expressed as a ratio of infectivity in autologous PBMCs that express high
levels of CD4 and CCR5. The shaded area highlights the time prior and during coreceptor switch. For sgp120 CD4-Ig binding, data are the means
and standard deviations from at least two independent experiments. For infection of macrophages, data are representative of at least 3
independent experiments (error bars, s.d.). * indicates statistically significant differences between the early and the evolving R5 viruses. (B)
Changes in neutralization sensitivity of R5 viruses evolving over time in macaques DE86 and DG08. Susceptibility of R5 pseudoviruses to
neutralization with IgG1b12, 447-52D and T20 was determined. The vertical dashed line indicates the time of coreceptor switching, and the
shaded area designates the period of marked envelope conformational changes. Data are representative of at least two independent experiments
(error bars, s.d.). * above the bars indicate IC50 values that are statistically different between the acute and the evolving R5 viruses, P<0.05 (Mann-
Whitney U test).
Figure 4 Entry efficiency, PSC-RANTES and sCD4 sensitivity of R5 viruses evolving over time in BT78, CC39 and DN57. Entry of luciferase
reporter viruses expressing CCR5-using Envs into TZM-bl cells expressed as relative light unit (RLU) (A), and susceptibility of the reporter viruses to
neutralization with PSC-RANTES (B) and sCD4 (C) were determined. The numbers in the brackets indicate the number of clones analyzed at each
time point and values above the bars indicate fold increase in sCD4 sensitivity relative to that of the w2 viruses. * P<0.05 (Mann-Whitney U test).
Data are representative of 2-3 independent experiments (error bars, s.d.).
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viruses, a 3-fold increase in sCD4 sensitivity was seen as
early as 4 wpi, with further increases (8-13 fold) for the
late viruses (w17, 25 and w30). Notably, an increase in
the ability of the evolving viruses to infect macrophages
was seen in all three RPs. The increase was significant
for the w4 viruses in CC39 as compared to the w1
viruses (p<0.05), with differences that approach signifi-
cance for the w9 and w12 viruses in this animal (p=0.07
and p=0.09, respectively). For BT78 and DN57, the dif-
ference in the ability to infect CD4
low cells between the
acute and late viruses was significant. Importantly, how-
ever, there was no corresponding increase in the ability
of the gp120s of the evolving R5 viruses in these animals
to bind CD4-Ig that would indicate increase accessibility
of the CD4 binding site (Figure 5A). We recognize that
CD4 binding was measured using monomeric gp120 and
may differ from that of trimeric gp120. Nevertheless, be-
cause the comparison is between CD4 binding of mono-
meric gp120s evolving over time in macaques with and
without coreceptor switch, the finding that increased
gp120/CD4 binding is observed only in animals with
tropism switch is still of interest. Thus, we conclude that
while the selective pressure for infection of alternative
target cells with lower receptor expression levels is
present in RPs with and without coreceptor switch, R5
viruses in macaques that did not switch evolved to be
more sCD4 sensitive and infected CD4
low cells more effi-
ciently via a mechanism other than adoption of an
“open” Env conformation to expose their CD4BS for bet-
ter receptor binding.
R5 viruses in RPs without coreceptor switch employ a
compensatory mechanism for poor CD4 binding in
infection of macrophages and in sCD4 susceptibility
Besides exposure of the CD4BS for efficient CD4 binding,
increase sensitivity to sCD4 neutralization and infection
of CD4
low cells may mean that the conformational
changes induced by CD4 binding are altered, that the
virus has acquired additional contacts with CD4, or the
interaction with CCR5 is improved [42-48]. The greater
resistance to PSC-RANTES inhibition of the late viruses
Figure 5 Enhanced macrophage infection accompanied by Env structural changes in R5 viruses evolving over time in macaques BT78,
CC39 and DN57. The relationship between sCD4 sensitivity, binding of sgp120 to CD4-Ig, infectivity of primary macrophages (mΦ)( A), and
neutralization susceptibility (B) of pseudoviruses bearing CCR5-using Envs amplified over time from BT78, CC39 and DN57 is shown. Data are
representative of at least two independent experiments (error bars, s.d.). * above bars indicate differences in sCD4 sensitivity, CD4-Ig binding and
susceptibility to agents and antibodies between the acute (w2) and the evolving R5 viruses that are statistically significant, * P<0.05 (Mann-
Whitney U test).
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coreceptor, and changes in gp41 HR1 has been associated
with SIV macrophage tropism [49,50]. To further under-
stand the mechanistic basis for increase sCD4 sensitivity
and infection of CD4
low cells of the evolving R5 viruses
in BT78 and DN57, their antigenic structure was exam-
ined. We found that the late viruses in BT78 (w13) and
DN57 (w17, 25 and 30) were significantly more sensitive
to IgGb12 (>3–fold), suggesting alteration in the struc-
ture of the CD4BS of these viruses that could provide
additional CD4 contacts. Changes in susceptibility to the
anti-V3 mAb 447-52D were also seen for BT78 and
DN57, with significant increase in sensitivity for the late
viruses in DN57 that may be indicative of the exposure
of the V3 loop. Moreover, the late viruses in DN57 were
significantly more sensitive to T20, which has been cor-
related with enhanced exposure of the HR1 fusion do-
main in gp41. Similar changes were seen for in CC39,
with significant increases in IgGb12 and T20 sensitivity
seen for the w6 and w9 viruses. Increase CD4 contact,
exposure of the V3 loop and HR1 groove for virus fusion
therefore could have compensated for the poor CD4
binding of the late viruses in the three macaques in
conferring sCD4 sensitivity and in adapting to less-
than-optimal CD4 molecules for entry into primary
macrophages.
High-level replication is a strong predictor for R5-to-X4
virus evolution in RPs
The finding that not all SHIVSF162P3N –infected RP
macaques adapt to use low levels of CD4 through adop-
tion of an “open” Env to enhance CD4 binding, even
though such an Env configuration would have relieved
the structural constraints on change in coreceptor pre-
ference, suggests that there is no obligatory selection
pressure for the virus to use CXCR4. It also implies that
the absence or diminution of antibody-driven pressure
by itself is insufficient to drive coreceptor switching, and
is consistent with our report that depletion of B cells to
abrogate or diminish antiviral antibody responses prior
to infection of rhesus macaques with SHIVSF162P3N did
not promote tropism switch [51]. In a number of cross-
section studies of HIV-1-infected individuals, high viral
load was shown to be the strongest predictor of R5-to-
X4 evolution [37,52-59]. To determine if high viral load
is also a predictor to R5-to-X4 evolution in RP maca-
ques, we compared cumulative viral loads up to the time
of euthanasia in R5 SHIVSF162P3N-infected RPs with
(n=4) and without (n=3) coreceptor switch studied here
and previously [30]. We found that cumulative viral load
was significantly higher in monkeys with tropism switch
than in those without, with a p value of 0.03 (Figure 6).
Thus, similar to HIV-1 infection in humans, high virus
replication is associated with the evolution and establish-
ment of X4 variants in R5 SHIV-infected macaques.
Discussion
In this study, we confirmed adoption of an "open" Env
to expose the CD4 binding site for efficient CD4 binding
and infection of primary macrophages in two additional
RPs with coreceptor switch. Moreover, changes in neu-
tralizing antibody and T20 sensitivity around the time of
X4 virus emergence are consistent with a more respon-
sive quaternary configuration of the viral envelope spike.
In agreement with reports in HIV-1-infected individuals,
high virus replication is a strong predictor for R5-to-X4
conversion in SHIVSF162P3N-infected macaques. A cer-
tain level of viremia may provide the conditions optimal
for coreceptor switching or, alternatively, the Env
changes required for coreceptor switching may predis-
pose to higher levels of virus replication. Adoption of an
"open" Env conformation that confers structural flexibil-
ity to accommodate mutational changes, and high levels
of virus replication to overcome the genetic hurdles for
R5-to-X4 evolution therefore contribute to the corecep-
tor switch in nonhuman primates. Since an "open" Env
conformation also renders the virus more susceptible to
antibody neutralization, our findings help to explain the
infrequent and late appearance of X4 virus in HIV-1 in-
fection when the immune system deteriorates.
Figure 6 Comparison of cumulative viral load in R5
SHIVSF162P3N-infected RPs with (n=4) and without (n=3)
coreceptor switch. Cumulative log10 RNA copies/ml of plasma
viremia up to the time of euthanasia were compared using unpaired
t tests. Time to euthanasia for the four RPs with coreceptor switch is:
w24 (BR24), w15 (CA28), w12 (DE86), w20 (DG08), and for the three
RPs without coreceptor switch is: w13 (BT78), w12 (CC39) and w30
(DN57). P value of <0.05 was considered significant.
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following the time of switch, with increase in PSC-
RANTES sensitivity that is suggestive of poorer CCR5
usage was seen in DG08 studied here (Figure 2) and in
BR24 and CA28 reported earlier [30]. Interestingly, these
are the three R5 SHIVSF162P3N-infected RPs that har-
bored pure X4 virus populations. Decrease in the effi-
ciency of CCR5 usage had also been reported in HIV-1
infected individuals with detectable CXCR4-using var-
iants [6,34,35], suggestive of a decline in R5 fitness. HIV-
1 and SHIV viruses with a pure X4 phenotype generally
have higher replication kinetics in vitro [60-64] and
in vivo [65-68]. Coupled with the broader cellular host
range of X4 viruses in vivo [69,70], they are likely to
out-compete R5 viruses once established. The decrease
in the selective pressure for R5 viruses to maintain opti-
mal replicative capacity and fitness with X4 emergence
therefore, could be a reason for the decrease in entry ef-
ficiency and CCR5 utilization of R5 viruses in SHIV-
infected macaques with pure X4 viruses. Nevertheless,
R5 variants persist following the appearance of X4
viruses in these animals, perhaps because of their dis-
tinct target cell range [69,70].
Transmitted/founder viruses in acute and early HIV-1
infection have been reported to be sCD4 resistant and to
replicate poorly in monocyte-derived macrophages that
express low levels of the CD4 receptor [3,71,72].
Neutralization resistance in vitro is often accompanied
by an increase in HIV-1 dependence on CD4 for entry
[73-75]. Indeed, founder viruses were shown to require
high levels of CD4 for entry [76], which may explain
their deficiency in infecting CD4
low cells. Consistent
with these findings in humans, viruses that are sCD4
resistant and infected primary macrophages less effi-
ciently predominated during acute infection in R5
SHIVSF162P3N-infected RP macaques DE86, BT78, CC39
and DN57, and in the two RPs we previously studied
[30], regardless of coreceptor switching. The exception
was DG08, where the acute (w2) viruses were observed
to be sCD4 sensitive but did not infect macrophages effi-
ciently. This however, was rapidly replaced two weeks
later by variants that are more resistant to sCD4, reinfor-
cing the view that these viruses are selected for during
primary infection. As this was observed despite intraven-
ous inoculation (BR24, CA28, DE86, BT78, CC39) which
circumvented mucosal barriers, and in macaques that
failed to mount a strong humoral or cellular immune re-
sponse, these factors are unlikely to be playing a role in
the early expansion of sCD4-resistant viruses. We specu-
late that the abundance of target cells with high levels of
cell surface CD4 expression in the new hosts maybe an
underlying determinant for the expansion and propaga-
tion of viruses that are more dependent on CD4 for entry
during acute SHIVSF162P3N infection in macaques and
HIV-1 infection in humans. Further research on the im-
portance of CD4 receptor density in HIV infection as
well as the kinetics of virus replication in infected cells
may help to understand the selective forces that govern
the biological phenotype of HIV-1 transmitted founder
viruses.
Enhanced infection of primary macrophages was seen
in the RP macaques at end-stage disease irrespective of
coreceptor switch, indicative of a strong selective pres-
sure to replicate in cells with lower CD4 cell-surface
expression levels over the infection course. Adaptation
to macrophages has also be observed in SIV-infected
RP macaques [77], and isolates from late in disease of
HIV-1 infected individuals have been reported to be
more macrophage-tropic compared to those from early
in infection [78-80], suggestive of similar selection
pressure in humans and rhesus monkeys. Presumably,
as discussed above, ongoing virus replication in both
hosts leads to loss in target cells (e.g., memory T cells)
with high receptor expression levels, putting pressure
on the virus to change so that it can use CD4 more ef-
ficiently to infect alternate CCR5+ cells such as macro-
phages that express low amounts of receptor.
Infection-associated immune activation may also de-
crease receptor density, since CD4 is down-regulated
with T-cell activation [81-83]. In RPs with coreceptor
switch (BR24, CA28, DE86, DG08), infection of CD4
low
cells was achieved by adoption of a less constrained
and more “open” Env conformation that exposes the
CD4 binding site for better CD4 binding, allowing
flexibility in accommodating the structural remodeling
needed for the change in coreceptor preference. The
V3 loop mutations that confer CXCR4 usage in R5
SHIVSF162P3N-infected RP monkeys and in HIV-1
infected individuals also render the virus sCD4 sensi-
tive, consistent with the notion that improved CD4
binding is a necessary prerequisite for acquisition of
CXCR4 use [23,84,85]. In RP macaques that did not
switch, R5 viruses appeared to have evolved to com-
pensate for inadequate CD4 binding by improving
CCR5 usage and/or the requisite post-binding conform-
ational changes for virus entry in response to non-
optimal CD4. It is possible that given time, these latter
macaques (e.g. BT78, CC39) could also adopt an
“open” Env conformation to facilitate CD4 binding and
infection of primary macrophages, setting the stage to
tropism switch. Alternatively, the presence of host im-
mune response may be a hindering factor. This is best
illustrated in DN57, which, contrary to the other RP
monkeys, mounted a persistent albeit weak anti-SHIV
antibody response. R5 viruses evolved in this macaque
to be highly sCD4 sensitive, with IC50 values compar-
able to those seen in DE86, suggestive of a similar
strong selective pressure for better CD4 usage. The
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efficiently, but this was not accompanied by a corre-
sponding increase in CD4 binding that is indicative of
exposure of the receptor binding site. Rather, the Envs
in DN57 evolved to adapt to less-than-optimal CD4
density by changes in receptor and/or coreceptor con-
tact, or by acquiring a higher propensity for proceeding
to fusion. Thus, although the pressure to infect cell tar-
gets that express low levels of CD4 is present in
SHIVSF162P3N-infected RP macaques regardless of core-
ceptor switch, the mechanisms employed to overcome
this selective pressure vary depending on other condi-
tions in the host.
Conclusions
In summary, our studies revealed an ordered process of
phenotypic switch that is now recapitulated in four R5
SHIVSF162P3N-infected RPs. The data reinforce the view
that an interplay between positive (e.g., magnitude of
persistent virus replication, evolutionary rate, change in
target cell population) and negative (e.g., host immune
response) selection forces that differ between individual
hosts and at different stages of the infection course gov-
erns how R5 viruses respond to the changing environ-
ment and shape the frequency of expansion or switch to
CXCR4 use. Greater viral burden translates into a faster
reduction in the target cell population, higher mutation
frequencies of the virus populations and increased
chances of X4 evolution. In the absence of immuno-
logical constraints in the RPs, and with the conferred
selective advantage of expanding cellular host range,
X4-associated changes become fixed and these viruses
rapidly spread. Since an "open" Env conformation for
improved CD4 binding and infection of CD4
low cells
also renders the virus more susceptible to antibody
neutralization, our findings may explain the infrequent
and late appearance of X4 virus in typical progressors
of HIV-1 infection.
Methods
Ethics statement
This work used blood from SHIV infected macaques
housed at the Tulane National Primate Research Center
(TNPRC) in accordance with the Animal Welfare Act
and Guide for the Care and Use of Laboratory Animals.
TNPRC is accredited by the Association and Assessment
and Accreditation of Laboratory Animal Care (AAALAC
#00594). The OLAW animal welfare assurance number
for TNPRC is A4499-01 and the USDA registration
number is 72-R-002. All procedures were performed on
anesthetized animals and post-operative analgesics were
administered as needed in accordance with the Tulane
IACUC approval.
Cells
293T cells and Hela TZM-bl cells expressing CD4, CCR5
and CXCR4 and containing integrated reporter genes for
firefly luciferase and β-galactosidase under control of the
HIV-1 LTR [86] were maintained in DMEM supplemen-
ted with 10% fetal bovine serum (FCS), 100 U/ml peni-
cillin, 100 μg/ml streptomycin and 2 mM L-glutamine.
Human peripheral mononuclear cells (PBMCs) were pre-
pared by Ficoll gradient centrifugation, stimulated with
phytohemagglutinin (PHA, 3 μg/ml; Sigma, St. Louis,
MO) in RPMI medium containing 10% FCS, penicillin,
streptomycin, L-glutamine and 20 U/ml interleukin-2
(Norvatis, Emeryville, CA). Monocytes were enriched by
centrifugation of PBMCs through a 40% percoll cushion
followed by plastic adherence, and cultured in RPMI 1640
medium supplemented with 10% FCS and 5% human AB
serum for 5-7 days to allow for differentiation into macro-
phages [87].
Detection of antiviral humoral response
SHIV-specific antibodies in serum samples were mea-
sured by enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (GS HIV-1/
HIV-2 PLUS O EIA; Bio-Rad, Redmond, WA). This
assay detects antibodies to HIV-1 gp160 and p24, and to
the immunodominant region of the transmembrane
glycoprotein gp36 of HIV-2. Optical density values at a
1:10 serum dilution that are three times above the cutoff
value are considered positive.
Plasmid constructs and pseudotyped virus production
For expression of envelope glycoproteins (Env), viral
RNA was prepared from 300-500 μl plasma using a
commercially available RNA extraction kit (Qiagen,
Chatsworth, CA) followed by reverse-transcription (RT)
with Superscript III RT (Invitrogen, Carlsbad, CA) and
random hexamer primers (Amersham Pharmacia, Piscat-
away, NJ). Full-length gp160 coding sequences were ampli-
fied from bulk RT products with primers SH43 (5
0-
AAGACAGAATTCATGAGAGTGAAGGGGATCAGGA
AG-3
0) and SH44 (5
0-AGAGAGGGATCCTTATAGCAA
AGCCCTTTCAAAGCCCT-3
0), subcloned into the
pCAGGS vector and sequenced for verification. To gen-
erate luciferase reporter viruses capable of only a single
round of replication, envelope trans-complementation
assay was used as previously described [88]. Briefly, Env
expression plasmid and the NL4.3LucE-R+ vector were
cotransfected with polyethylenimine (PEI, Polyscience,
Warrington, PA) into 2.5 × 10
6 293T cells plated in a
100-mm plate. Cell culture supernatants were harvested
72 hours later, filtered through 0.45-μmf i l t e r s ,a n d
stored at -70°C in 1-ml aliquots. Pseudotyped viruses
were quantified for p24 Gag content (Beckman Coulter,
Fullerton, CA).
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For assessment of Env functionality and entry efficiency,
7×1 0
3 TZM-bl cells were seeded in 96-well plates 24
hours before use and infected, in triplicates, with 2 ng
p24 Gag equivalent of the indicated pseudotyped viruses.
Infected cells were cultured for 72 h at 37°C, at which
time the cells were harvested, lysed and processed for
luciferase activity according to the manufacturer’si n s t r u c -
tions (Luciferase Assay System; Promega, Madison, WI).
Entry, as quantified by luciferase activity, was measured
with an MLX microtiter plate luminometer (Dynex Tech-
nologies, Inc., Chantilly, VA). For infection of primary
cells, 10
5 and 10
6 cells of human PBMCs and macrophage
respectively were infected in duplicates with 5 ng p24 Gag
equivalent of the indicated pseudotyped viruses in each
well of a 96-well plate. Infected cultures were harvested 72
hours later and processed for luciferase activity. To con-
trol for differences in Env entry efficiencies, infectivity in
macrophages was expressed as a ratio of the infectivity for
these cells compared to the infectivity in PBMCs from the
same donor.
Receptor and coreceptor usage efficiency
For assessment of receptor usage efficiency, 2 ng p24
equivalent of the indicated pseudotyped viruses in 50 μl
were incubated with equal 4-fold serial dilution volumes
of CD4-IgG2 fusion protein (sCD4; PRO 542, Progenics
Pharmaceuticals, Tarrytown, NY) for 1 h at 37°C and
then added to cells, in duplicate wells, for an additional
2 hours at 37°C. 100 μl of medium was then added to
each well and the virus-protein cultures maintained for
72 hours. Control cultures received virus in the absence
of sCD4. At the end of the culture period, the cells were
lysed and processed for β-galactosidase activity (Galacto-
Star System; Applied Biosystems, Bedford, MA). A
neutralization curve was generated by plotting the per-
centage of neutralization vs sCD4 dilution, and 50% in-
hibitory concentrations (IC50) were determined using
the Prism 4 software (GraphPad, San Diego, CA). For as-
sessment of coreceptor usage efficiency, 7 × 10
3 TZM-bl
cells per well of a 96-well plate were inoculated, in
duplicates, with 2 ng p24 Gag antigen equivalent of the
indicated pseudotyped virus in the absence or presence
of 4-fold dilutions of the CCR5 antagonist PSC-
RANTES. The cells were lysed after 72 hours at 37°C,
processed for β-galactosidase activity, and IC50 deter-
mined using the Prism 4 software.
Soluble gp120-CD4-Ig binding
To examine monomeric gp120-CD4 binding, gp120
glycoproteins from transfected 293T cells were meta-
bolically radiolabeled for 48 hours with 100 μCi/mL
[35S]-methionine/cysteine ([35S] protein labeling mix;
Perkin-Elmer, Waltham, Mass) in Dulbecco's modified
Eagle's medium lacking methionine and cysteine and
supplemented with 5% dialyzed fetal bovine serum.
Radiolabeled protein extracts were incubated with ei-
ther a mixture of sera from HIV-1 infected individuals
or CD4-Ig (a fusion protein in which the N-terminal
two domains of CD4 are linked to the Fc component
of immunoglobulin G [89]) in the presence of 70 μlo f
10% Protein A-Sepharose (American BioSciences Inc,
Boulder, CO) for 2 hr at 37ºC. The precipitates were
analyzed on NuPAGE Novex Bis-Tris polyacrylamide
gels (Invitrogen, Carlsbad, CA), followed by autoradiog-
raphy and quantification with a PhosphorImager (Mo-
lecular Dynamics, Sunnyvale, CA).
Neutralization assay
Virus neutralization was assessed using TZM-bl cells in
96-well plates. Briefly, equal volumes (50 μl) of pseudo-
typed viruses (2-3 ng p24 Gag equivalent) and 4-fold ser-
ial dilutions of IgG1b12, 443-52D and T20 were
incubated for 1 h at 37°C and then added to cells, in du-
plicate wells, for an additional 2 hours at 37°C. 100 μlo f
medium was then added to each well and the virus-
protein cultures maintained for 72 hours. Control cul-
tures received virus in the absence of blocking agent. At
the end of the culture period, the cells were lysed and
processed for β-galactosidase activity. A neutralization
curve was generated by plotting the percentage of
neutralization vs agent dilution, and IC50 determined
using the Prism 4 software.
Statistical analysis
The Mann-Whitney U or unpaired T test was used to
evaluate differences in susceptibility to sCD4, 1b12, 447-
52D and T20; binding of gp120 to CD4-Ig; and infection
of macrophages between the early (w2-4) and the evolv-
ing R5 viruses. These tests were also used to examine
differences in cumulative viral load between RPs with
and without coreceptor switch. P-values <0.05 were con-
sidered statistically significant.
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